A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer

被引:47
|
作者
Gemer, O
Lurian, M
Gdalevich, M
Kapustian, V
Piura, E
Schneider, D
Lavie, O
Levy, T
Fishman, A
Dgani, R
Levavi, H
Beller, U
机构
[1] Ben Gurion Univ Negev, Dept Obstet & Gynecol, Barzilai Med Ctr, IL-84105 Beer Sheva, Israel
[2] Dist Hlth Off, Ashqelon, Israel
[3] Soroka Med Ctr, IL-84101 Beer Sheva, Israel
[4] Assaf Harofe Med Ctr, Zerifin, Israel
[5] Carmel Hosp, Haifa, Israel
[6] Wolfson Med Ctr, Holon, Israel
[7] Meir Med Ctr, Kefar Sava, Israel
[8] Kaplan Med Ctr, Rehovot, Israel
[9] Rabin Med Ctr, Petah Tiqwa, Israel
[10] Shaare Zedek Med Ctr, Jerusalem, Israel
来源
EJSO | 2005年 / 31卷 / 09期
关键词
epithelial ovarian cancer; CA; 125; cytoreduction; prediction;
D O I
10.1016/j.ejso.2005.05.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To provide a large database of pre-operative CA 125 levels which may predict inappropriate cytoreductive surgery in patients with advanced epithelial, ovarian cancer. Methods: A multicenter review of the records of 424 patients with FIGO stage III and IV epithelial. ovarian cancer of patients who underwent primary cytoreductive surgery was performed. The validity of pre-operative CA 125 level measurement as a single predictor of the possibility to achieve only suboptimal cytoreduction was evaluated by calculating the sensitivity and the specificity of various cut-off values. The relative importance of different cut-off values in achieving the best predictive validity was assessed by a receiver operating characteristics (ROC) curve. Results: Optimal cytoreduction (largest diameter of residual tumour <= 1 cm) was achieved in 242 patients. The median CA 125 level in optimally cytoreduced patients was lower than in those patients suboptimally debulked (304 vs 863 U/mL; p < 0.001). The area under the ROC curve was 0.65 (95% confidence interval, 0.60-0.71) and the CA 125 threshold derived from the ROC was 400 U/mL. The accuracy of the test at this level was 62%. Conclusions: The clinical applicability of the ROC derived CA 125 threshold is limited. The data accrued in the study provides a basis for decision-making regarding the place of primary surgery various CA 125 levels. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1006 / 1010
页数:5
相关论文
共 50 条
  • [41] NOT OPTIMAL PRIMARY CYTOREDUCTION MORE FREQUENTLY IN BRCA MUTATIONS CARRIERS WITH ADVANCED OVARIAN CANCER.
    Stukan, M.
    Ratajska, M.
    Dudziak, M.
    Limon, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1503 - 1503
  • [42] Comparative Study Between Serum Level of Lysophosphatidic Acid and CA-125 in Epithelial Ovarian Cancer
    Rady H.A.
    Othman M.M.
    Agamia A.F.M.
    Mahmoud M.H.
    Elghrabawy S.A.
    [J]. Indian Journal of Gynecologic Oncology, 2018, 16 (3)
  • [43] Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer
    Brockbank, EC
    Ind, TEJ
    Barton, DPJ
    Shepherd, JH
    Gore, ME
    A'Hern, R
    Bridges, JE
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (01) : 42 - 50
  • [44] CLINICOPATHOLOGICAL BACKGROUND AND PROGNOSIS OF ADVANCED OVARIAN CANCER PATIENTS WITHOUT OPTIMAL CYTOREDUCTION AT PRIMARY SURGERY
    Saotome, K.
    Nomura, H.
    Dozen, A.
    Nanki, Y.
    Yoshihama, T.
    Iwasa, N.
    Chiyoda, T.
    Yamagami, W.
    Kataoka, F.
    Hirasawa, A.
    Aoki, D.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 828 - 828
  • [45] Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer
    Ducoulombier, Simon
    Golfier, Francois
    Colomban, Olivier
    Benayoun, David
    Bolze, Pierre-Adrien
    Tod, Michel
    You, Benoit
    [J]. ANTICANCER RESEARCH, 2017, 37 (12) : 6879 - 6886
  • [46] Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer
    Nielsen, HA
    Nielsen, D
    Engelholm, SA
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 77 (03) : 383 - 388
  • [47] Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Kang, Sokbom
    Kim, Tae-Joong
    Seo, Sang-Soo
    Kim, Byoung-Gie
    Bae, Duk-Soo
    Park, Sang-Yoon
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 18 - 22
  • [48] A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer
    Suidan, Rudy S.
    Ramirez, Pedro T.
    Sarasohn, Debra M.
    Teitcher, Jerrold B.
    Iyer, Revathy B.
    Zhou, Qin
    Iasonos, Alexia
    Denesopolis, John
    Zivanovic, Oliver
    Roche, Kara C. Long
    Sonoda, Yukio
    Coleman, Robert L.
    Abu-Rustum, Nadeem R.
    Hricak, Hedvig
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 145 (01) : 27 - 31
  • [49] Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer
    Zang R.Y.
    Li Z.T.
    Tang J.
    Huang X.
    Cai S.M.
    [J]. World Journal of Surgical Oncology, 4 (1)
  • [50] Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer
    Qayyum, A
    Coakley, FV
    Westphalen, AC
    Hricak, H
    Okuno, WT
    Powell, B
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 96 (02) : 301 - 306